Edition:
United States

Insight: Chasing cheaper cancer drugs

Photographer
RUPAK DE CHOWDHURI

A girl suffering from cancer rests inside the children's ward at the Cancer Centre Welfare Home and Research Institute in Kolkata March 16, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug...more

A girl suffering from cancer rests inside the children's ward at the Cancer Centre Welfare Home and Research Institute in Kolkata March 16, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug Nexavar and issuing its first-ever compulsory licence, allowing local generic firm Natco Pharma to produce and sell the drug cheaply in India. In a move to head off the same threat to its patented drugs, Roche, the world's biggest maker of cancer medicines, plans to offer significantly cheaper locally branded versions of two other cancer treatments, Herceptin and MabThera, under an alliance with Emcure Pharmaceuticals. Picture taken March 16, 2012. REUTERS/Rupak De Chowdhuri/Files
Close
1 / 2
Photographer
VIVEK PRAKASH

A woman with cancer sits on a pavement outside the Tata Memorial Hospital in Mumbai March 15, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug Nexavar and issuing its first-ever compulsory...more

A woman with cancer sits on a pavement outside the Tata Memorial Hospital in Mumbai March 15, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug Nexavar and issuing its first-ever compulsory licence, allowing local generic firm Natco Pharma to produce and sell the drug cheaply in India.In a move to head off the same threat to its patented drugs, Roche, the world's biggest maker of cancer medicines, plans to offer significantly cheaper locally branded versions of two other cancer treatments, Herceptin and MabThera, under an alliance with Emcure Pharmaceuticals. Picture taken March 15, 2012. REUTERS/Vivek Prakash/Files
Close
2 / 2

All Collections

The attack on Pearl Harbor

1:06pm EST

All Collections

In memoriam: Those we lost in 2016

10:10am EST

All Collections

Trump: Person of the year

8:20am EST

All Collections

Libyan forces clear Islamic State from Sirte

Tuesday, December 06, 2016

All Collections

Taking off with Air Force One

Tuesday, December 06, 2016

All Collections

Chanel cosmopolite in Paris

Tuesday, December 06, 2016

All Collections

Last in a remote Siberian village

Tuesday, December 06, 2016

All Collections

Winter sets in on the North Dakota Pipeline Protest

Tuesday, December 06, 2016